NasdaqGS:VRTXBiotechs
Why Vertex Pharmaceuticals (VRTX) Is Up 6.0% After Profit Rebound And Non-CF Pipeline Update - And What's Next
Vertex Pharmaceuticals reported full-year 2025 results showing revenue of US$12.00 billion, up from US$11.02 billion a year earlier, with net income of US$3.95 billion replacing a net loss and earnings per share turning positive on both a basic and diluted basis.
Alongside this earnings shift, Vertex issued 2026 guidance that points to an increasing contribution from non-cystic fibrosis products such as CASGEVY and JOURNAVX, supported by a new trispecific T‑cell engager collaboration with...